FDA approves new ‘King Kong’ weight loss drug

Potential blockbuster dubbed Zepbound to join cousin drug Mounjaro on US market Tirzepatide, Eli Lilly’s GIP and GLP-1 agonist, described by media as “the King Kong of drugs”, has been approved for weight loss by the US Food and Drug Administration (FDA) under the brand name Zepbound. Similar to the way Novo Nordisk has marketed